DARPA (BTO): Rapid Inhibitor Discovery and Development pipeLine (RIDDL)

The Rapid Inhibitor Discovery and Development pipeLine (RIDDL) program explicitly seeks transformative approaches that enable the rapid discovery, design, and development of novel inhibitors with enhanced activity, specificity, utility, and potency for gene editing technologies.

Of particular interest are commonly used gene editors such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated proteins (CRISPR-Cas) nucleases; gene editing technologies beyond CRISPR-Cas systems are also of interest to keep pace with the rapidly advancing field and promote the safe, controlled use of these technologies.

Funding: no fixed limit 

Duration: 30 months 

Research Authority due date: 12.12.24